Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
March 11, 2025 | 07:00
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Michael D. Patten as Chief Strategy Officer.
Mobile Version
